Business Context and Reporting Period
Company: TherapeuticsMD, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 30, 2018 (Events reported through August 2, 2018)
Context: The filing details the entry into material definitive agreements regarding the licensing of contraceptive and menopause products, an amendment to a credit agreement, and the execution of equity financing transactions.
Key Financial Metrics and Agreements
Equity Financing:
- Public Offering: Underwritten public offering of 12,745,098 shares of Common Stock, with the underwriters exercising their option to purchase an additional 1,911,764 shares.
- Expected Net Proceeds: Approximately $70.0 million from the public offering.
- Registered Direct Offering: Knight Therapeutics Inc. agreed to purchase $20 million of Common Stock.
License Agreement Obligations (Population Council):
- Milestone Payments: $20 million upon FDA approval of the one-year vaginal contraceptive system; $20 million upon release of the first commercial batch.
- Sales Milestones: $40 million payable upon cumulative net sales reaching $200 million, $400 million, and $1 billion.
- Royalties: Step-based royalties ranging from 5% to 15% of annual net sales in the U.S., subject to reductions upon generic entry.
Credit Agreement Amendment:
- Condition Precedent: The Company must receive aggregate net cash proceeds of at least $75 million from equity issuance within 30 days of the license agreement to avoid an automatic event of default.
Material Changes and Strategic Developments
Population Council License (Item 1.01):
- Entered an exclusive license agreement to commercialize the segesterone acetate/ethinyl estradiol one-year vaginal system in the U.S.
- The New Drug Application (NDA) is under FDA review with a PDUFA target action date of August 17, 2018.
- Includes rights to negotiate co-development and marketing for two additional investigational vaginal contraceptive systems.
Knight Therapeutics License (Item 8.01):
- Granted Knight Therapeutics an exclusive license to commercialize Imvexxy (estradiol vaginal inserts) and investigational TX-001HR in Canada and Israel.
- Compensation includes milestone fees upon regulatory approval, sales milestones, and royalties.
- Knight's $20 million equity investment is contingent on the closing of the Company's underwritten public offering.
Outlook, Risks, and Contingencies
Regulatory Risks:
- The Population Council license may be terminated if the FDA issues a complete response letter, requires a continuance greater than 90 days, or approves the product with post-marketing requirements exceeding $1 million (beyond standard studies).
- Termination rights exist if the product is approved with a shelf life of less than 18 months or is not granted "new chemical entity" status.
Financial Contingencies:
- Default Risk: Failure to raise at least $75 million in net equity proceeds within 30 days of the license agreement constitutes an automatic event of default under the Credit Agreement.
- Investment Contingency: Knight Therapeutics' $20 million investment is tied to the successful closing of the public offering; otherwise, an upfront license fee is payable.
Post-Approval Costs:
- The Company is responsible for a post-approval study on venous thromboembolism risk. Costs exceeding $20 million will be offset against royalties or other payments owed to the Population Council.
Investor Verification Checklist
- Equity Proceeds: Verify the actual closing date and net proceeds of the public offering and Knight Therapeutics' direct offering to ensure the $75 million credit agreement threshold is met.
- FDA Decision: Monitor the FDA's action on the NDA for the one-year vaginal contraceptive system by the August 17, 2018 PDUFA date.
- License Terms: Confirm whether the FDA approval includes any post-marketing requirements or shelf-life limitations that could trigger termination rights under the Population Council agreement.
- Capital Structure: Assess the dilution impact of the issuance of approximately 14.66 million shares in the public offering plus the shares issued to Knight Therapeutics.